With the FDA's acceptance of Urogen's NDA and issuance of an 06/13/2025 PDUFA the clock is now ticking for FDA approval of ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

even during cancer treatment. Scientists also revealed that circular fragments of DNA called extrachromosomal DNA (ecDNA) is ...

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

A bladder ultrasound gives providers clues about how the bladder expands and holds urine. This article lists conditions ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new study finds.

A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a ...

The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years ...

Researchers conducted a cohort study to try to characterize long-term treatment-related adverse effects and complications in ...